Director, Biostatistics Laboratory
Eric Polley, PhD is an Associate Professor in the Department of Public Health Sciences at The University of Chicago where he is the faculty director for the Data Science concentration in the Master of Public Health program. Dr. Polley was previously an Assistant Professor of Biostatistics in the Department of Quantitative Health Sciences at Mayo Clinic (2015-2021) and a mathematical statistician in the Biometric Research Branch at the U.S. National Cancer Institute (2012-2015). Dr. Polley received his PhD in biostatistics from the University of California, Berkeley in 2010. With Mark van der Laan, they developed the Super Learner ensemble prediction methodology. His research area involves the development and evaluation of prediction methods, innovative methods for diagnostic and prognostic prediction, and precision medicine clinical trial design.
National Cancer Institute
MD
Fellow - Computational Biology
2012
University of California, Berkeley
CA
PhD - Biostatistics
2010
Columbia University
NY
MS - Biostatistics
2005
Saint John's University
MN
BA - Mathematics
2003
Person-centered intervention response in primary progressive aphasia: A secondary analysis of the Communication Bridge-2 randomized clinical trial.
Person-centered intervention response in primary progressive aphasia: A secondary analysis of the Communication Bridge-2 randomized clinical trial. Alzheimers Dement (N Y). 2026 Apr-Jun; 12(2):e70283.
PMID: 42358427
Race-Neutral FRAX without BMD outperforms FRAX without BMD in a multiethnic cohort with Diabetes or Hypertension.
Race-Neutral FRAX without BMD outperforms FRAX without BMD in a multiethnic cohort with Diabetes or Hypertension. J Bone Miner Res. 2026 Jun 19.
PMID: 42319028
Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes.
Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes. Am J Kidney Dis. 2026 Jun 16.
PMID: 42302979
Comparative effectiveness of sulfonylureas on kidney outcomes in adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation.
Comparative effectiveness of sulfonylureas on kidney outcomes in adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation. BMJ Open Diabetes Res Care. 2026 May 21; 14(3).
PMID: 42167878
Comparative Effectiveness of Individual Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: Emulation of a Target Trial.
Comparative Effectiveness of Individual Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: Emulation of a Target Trial. J Am Heart Assoc. 2026 May 19; 15(10):e046238.
PMID: 42132163
Cardiovascular Effects of Alogliptin, Linagliptin, Saxagliptin, and Sitagliptin: A Target Trial Emulation of a Comparative Effectiveness Study.
Cardiovascular Effects of Alogliptin, Linagliptin, Saxagliptin, and Sitagliptin: A Target Trial Emulation of a Comparative Effectiveness Study. Endocr Pract. 2026 Apr 08.
PMID: 41962900
Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation.
Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation. BMJ Open Diabetes Res Care. 2026 Feb 26; 14(1).
PMID: 41760122
Lower Extremity Complications in Adults With Type 2 Diabetes Treated With Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas: An Emulated Target Trial.
Lower Extremity Complications in Adults With Type 2 Diabetes Treated With Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas: An Emulated Target Trial. Endocr Pract. 2026 Jun; 32(6):916-926.
PMID: 41638310
Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women.
Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women. JAMA Oncol. 2025 Dec 01; 11(12):1458-1469.
PMID: 41066089
Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial.
Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial. Diabetes Res Clin Pract. 2025 Nov; 229:112910.
PMID: 40983112
NCI Director's award for the development of the NCI-MATCH clinical trial
National Cancer Institute
2015